Asymptomatic aortic stenosis has been keeping us in tense stillness. However, there are new markers capable of identifying patients that might benefit from earlier intervention. In this regard, cardiovascular magnetic resonance (CMR) has been gaining its well-deserved place in cardiology and now more specifically in aortic stenosis. This study sought to validate CMR markers of<a href="https://solaci.org/en/2021/08/19/new-markers-of-aortic-stenosis-define-asymptomatic-patients/" title="Read more" >...</a>
SOLACI-CACI 2021 | International Sessions with the Most Renowned Societies Worldwide
INTERNATIONAL SESSIONS WITH THE MOST RENOWNED SOCIETIES WORLDWIDE Appealing sessions on the most relevant current topics in interventional cardiology will be at the forefront of a virtual, interactive event you do not want to miss! Save the date: August 2-6, 2021 Register now for FREE Learn more about the international joint sessions featured in<a href="https://solaci.org/en/2021/07/23/solaci-caci-2021-international-sessions-with-the-most-renowned-societies-worldwide/" title="Read more" >...</a>
TAVR Durability Becomes Irrelevant after TRANSIT Outcomes
The international registry TRANSIT has shown treating degenerated transcatheter aortic valves (TAVs) with a second TAVR is safe and effective. These finding are of crucial importance to the definite adoption of TAVR in the lower risk, younger population. Transcatheter aortic valve replacement (TAVR) has determined a paradigm shift in severe aortic stenosis treatment. Technological innovation<a href="https://solaci.org/en/2021/07/06/tavr-durability-becomes-irrelevant-after-transit-outcomes/" title="Read more" >...</a>
Direct TAVR vs. Predilation: Potential Cost of a Simpler Procedure
Does simplifying TAVR involve a cost? At least for low-risk patients included in the PARTNER 3, the question appears somewhat abstract. Predilation and direct TAVR resulted equally safe, though the latter shortened procedural time and did not require further post dilation. Both strategies resulted virtually identical in terms of clinical events. The use of predilation<a href="https://solaci.org/en/2021/06/30/direct-tavr-vs-predilation-potential-cost-of-a-simpler-procedure/" title="Read more" >...</a>
European Consensus on Antithrombotic Management in TAVR
All the controlled randomized evidence recently published called for an updated document on antithrombotic management in transcatheter aortic valve replacement (TAVR). While thrombotic and hemorrhagic complications have diminished over time—as both the technique and the devices have been perfected—, they still remain as common adverse events in TAVR. Recommendations in the 2017 European Guidelines were<a href="https://solaci.org/en/2021/06/28/european-consensus-on-antithrombotic-management-in-tavr/" title="Read more" >...</a>
Silent Embolism during TAVR: Just Images or Potential Cognitive Deterioration?
Finding new cerebral ischemic imaging after transcatheter aortic valve replacement (TAVR) is almost the rule, especially for self-expandable valves. These images might disappear over the months but, unfortunately, they are associated to small but significative cognitive deterioration. Most patients undergoing TAVR develop silent cerebral ischemic lesions (SCILs) that show in magnetic resonance imaging (MRI). The<a href="https://solaci.org/en/2021/06/23/silent-embolism-during-tavr-just-images-or-potential-cognitive-deterioration/" title="Read more" >...</a>
Post TAVR Acute Coronary Syndrome: Frequency and Potential Damage
After Transcatheter Aortic Valve Replacement (TAVR) acute coronary syndromes (ACS) are rare and mostly present as non-ST elevation events. In this context, the few ST elevation events have bad prognosis, with close to 30% mortality at 30 days. This study included patients undergoing TAVR between 2012 and 2017 admitted for acute coronary syndrome during followup. <a href="https://solaci.org/en/2021/06/22/post-tavr-acute-coronary-syndrome-frequency-and-potential-damage/" title="Read more" >...</a>
SOLACI/SIAC Latin American Clinical Guidelines on TAVR vs. SAVR Published
The Latin American Society of Interventional Cardiology is proud to announce that the Latin American Clinical Guidelines on TAVR vs. SAVR on patients with severe aortic stenosis have been published. This high-quality scientific work was published in the Heart BMJ Journal and is the result of an arduous joint effort between SOLACI (through its Research<a href="https://solaci.org/en/2021/06/16/solaci-siac-latin-american-clinical-guidelines-on-tavr-vs-savr-published/" title="Read more" >...</a>
AAS vs DAPT post TAVI: Meta-Analysis of Randomized Studies
Aspirin monotherapy (ASA) reduced the combined risk of thrombotic and bleeding events compared against dual antiplatelet therapy (DAPT) in patients receiving transcatheter aortic valve replacement (TAVR). This meta-analysis has only reproduced smaller randomize study outcomes and does not include the OCEAN-TAVI registry, the only one that has shown something different so far. Even though ASA<a href="https://solaci.org/en/2021/06/14/aas-vs-dapt-post-tavi-meta-analysis-of-randomized-studies/" title="Read more" >...</a>
Official Presentation of SOLACI / SIAC Latin American Clinical TAVR Guidelines
The Latin American Society of Interventional Cardiology (SOLACI) and the Inter-American Society of Cardiology (SIAC) have jointly developed their Clinical Guidelines on Transcatheter Aortic Valve Replacement (TAVR) to be presented this week at the Virtual SIAC Congress. The creation of these guidelines is the result of an important joint effort between SOLACI and SIAC during<a href="https://solaci.org/en/2021/06/09/official-presentation-of-solaci-siac-latin-american-clinical-tavr-guidelines/" title="Read more" >...</a>